安科生物 (300009)
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.
K-Line Chart
No K-line data
Company NameAnhui Anke Biotechnology (Group) Co., Ltd.
Listing Date2009-10-30
Issue Price17Yuan
Registered Capital167252.125810K Yuan
Legal RepresentativeSong Lihua
Registered AddressK-1 Haiguan Road, High-tech Zone, 669 Changjiang West Road, Hefei City, Anhui Province
IndustryBiological Products
Main BusinessResearch, development, production, and sales of biological products. Leading products are recombinant human interferon and recombinant human growth hormone series.
Company ProfileAnhui Anke Biotechnology (Group) Co., Ltd. is a national innovation pilot enterprise, a key high-tech enterprise under the National Torch Program, an industrialization base for achievements of the National '863' Program, and one of the first batch of companies listed on the ChiNext board.
Anke Biotechnology has long been committed to the research and development of pharmaceutical and medical technologies and products such as cell engineering products, genetic engineering products, and precision medicine, as well as building core technological capabilities. It has established a postdoctoral research workstation approved by the Ministry of Personnel, an Academician Workstation in Anhui Province, Anhui Province and Hefei City Genetic Drug Engineering Technology Research Center, Anhui Province Bioengineering Laboratory, and the Anhui Province Key Laboratory of Genetic Engineering Pharmaceuticals.
Stock Details
1. Key Indicators
- Total Shares(W): 167252.13
- Circulating A-Shares(W): 122957.78
- Earnings Per Share(RMB): 0.3300
- Net Assets Per Share(RMB): 2.4926
- Operating Revenue(W RMB): 196259.01
- Total Profit(W RMB): 64868.42
- Net Profit Attributable to Parent(W RMB): 55148.33
- Net Profit Growth Rate(%): -6.48
- Weighted Return on Equity(%): 13.5900
- Operating Cash Flow Per Share(RMB): 0.3320
- Undistributed Profit Per Share(RMB): 1.0490
- Capital Reserve Per Share(RMB): 0.2735
2. Main Business
The main business covers:
- Research, production, and sales of genetic engineering drugs
- Research, production, and sales of biological detection reagents
3. Company Basic Information
- Company Name: Anhui Anke Biotechnology (Group) Co., Ltd.
- Listing Date: 2009-10-30
- Industry: Pharmaceutical Manufacturing
- Address: No. K-1, Haiguan Road, High-tech Zone, 669 Changjiang West Road, Hefei City, Anhui Province
- Website: www.ankebio.com
- Company Profile: The Company was established as a joint stock limited company through the overall restructuring of Anhui Anke Biotechnology High-tech Co., Ltd. by its original shareholders, with the audited net assets of RMB 24,043,800 as of August 31, 2000 converted into 24 million shares, approved by the Anhui Provincial Economic Restructuring Commission (Document No. Wan Ti Gai Han [2000] 77) and the Anhui Provincial People's Government (Approval Certificate No. Wan Fu Gu Zi [2000] 34). The Company obtained its Business License on September 28, 2000. Currently, the Company's total share capital is 63 million shares.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 1952.26 | 1.60 |
| 2 | China Merchants Guozheng Bio-medicine Index Securities Investment Fund (LOF) Class A | Fund | 1596.17 | 1.31 |
| 3 | Yinhua CSI Innovative Pharmaceutical Industry Exchange Traded Fund | Fund | 1121.77 | 0.92 |
| 4 | Southern CSI 1000 Exchange Traded Fund | Fund | 1070.74 | 0.88 |
| 5 | Fullgoal Enhanced Return Bond Securities Investment Fund Class A | Fund | 900.00 | 0.74 |
| 6 | China Securities Industry Rotation Hybrid Securities Investment Fund Class A | Fund | 564.68 | 0.46 |
| 7 | China Securities Value Selection Hybrid Securities Investment Fund Class A | Fund | 370.05 | 0.30 |
| 8 | China Securities Strategy Selection Hybrid Securities Investment Fund Class A | Fund | 254.96 | 0.21 |
| 9 | Caitong Asset Management Health Industry Hybrid Securities Investment Fund Class A | Fund | 210.00 | 0.17 |
| 10 | China Securities Quality Preferred One-Year Holding Hybrid Securities Investment Fund Class A | Fund | 78.54 | 0.06 |
5. Concept Sectors
- Private Hospitals
- Gene Concept
- Immunotherapy
- Artificial Intelligence
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- AI Healthcare
- Margin Trading & Securities Lending
- Small Cap Growth
- SZSE Growth Index
- ChiNext 300
- ChiNext Innovation
- ChiNext Blue Chip
- ChiNext Quality
- ChiNext Pharmaceuticals
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information